{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:19:25Z","timestamp":1783682365499,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T00:00:00Z","timestamp":1582243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s40256-020-00394-1","type":"journal-article","created":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T05:18:18Z","timestamp":1582262298000},"page":"489-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study"],"prefix":"10.1007","volume":"20","author":[{"given":"Haiyan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yudong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuxiu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengmeng","family":"Shuai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Vitse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie T.","family":"Baccara-Dinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,21]]},"reference":[{"key":"394_CR1","volume-title":"Global Atlas on cardiovascular disease prevention and control","year":"2011","unstructured":"Mendis S, Puska P, Norving B, editors. Global Atlas on cardiovascular disease prevention and control. Geneva: World Health Organization; 2011."},{"key":"394_CR2","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.ijcard.2015.06.170","volume":"6","author":"H Li","year":"2015","unstructured":"Li H, Ge J. Cardiovascular diseases in China: current status and future perspectives. Int J Cardiol Heart Vasc. 2015;6:25\u201331.","journal-title":"Int J Cardiol Heart Vasc."},{"issue":"1","key":"394_CR3","first-page":"1","volume":"15","author":"Joint Committee for Guideline Revision","year":"2018","unstructured":"Joint Committee for Guideline Revision. 2016 Chinese guidelines for the management of dyslipidemia in adults. J Geriatr Cardiol. 2018;15(1):1\u201329.","journal-title":"J Geriatr Cardiol."},{"issue":"4","key":"394_CR4","first-page":"329","volume":"20","author":"WH Zhao","year":"2007","unstructured":"Zhao WH, Zhang J, Zhai Y, You Y, Man QQ, Wang CR, et al. Blood lipid profile and prevalence of dyslipidemia in Chinese adults. Biomed Environ Sci. 2007;20(4):329\u201335.","journal-title":"Biomed Environ Sci"},{"issue":"2","key":"394_CR5","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.atherosclerosis.2014.05.916","volume":"235","author":"S Zhao","year":"2014","unstructured":"Zhao S, Wang Y, Mu Y, Yu B, Ye P, Yan X, et al. Prevalence of dyslipidaemia in patients treated with lipid-lowering agents in China: results of the DYSlipidemia International Study (DYSIS). Atherosclerosis. 2014;235(2):463\u20139.","journal-title":"Atherosclerosis."},{"key":"394_CR6","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.2147\/TCRM.S178318","volume":"14","author":"J Jiang","year":"2018","unstructured":"Jiang J, Zhou YJ, Li JJ, Ge JB, Feng YQ, Huo Y. Uncontrolled hyperlipidemia in Chinese patients who experienced acute coronary syndrome: an observational study. Ther Clin Risk Manag. 2018;14:2255\u201364.","journal-title":"Ther Clin Risk Manag"},{"issue":"46","key":"394_CR7","doi-asserted-by":"publisher","first-page":"e8555","DOI":"10.1097\/MD.0000000000008555","volume":"96","author":"W Zheng","year":"2017","unstructured":"Zheng W, Zhang YJ, Bu XT, Guo XZ, Hu DY, Li ZQ, et al. LDL-cholesterol goal attainment under persistent lipid-lowering therapy in northeast China: Subgroup analysis of the dyslipidemia international study of China (DYSIS-China). Medicine. 2017;96(46):e8555.","journal-title":"Medicine."},{"issue":"39","key":"394_CR8","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, et al. 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999\u20133058.","journal-title":"Eur Heart J"},{"issue":"24","key":"394_CR9","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: a Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168\u2013209.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"394_CR10","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1073\/pnas.0335507100","volume":"100","author":"NG Seidah","year":"2003","unstructured":"Seidah NG, Benjannet S, Wickham L, Marcinkiewicz J, Jasmin SB, Stifani S, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci USA. 2003;100(3):928\u201333.","journal-title":"Proc Natl Acad Sci USA."},{"issue":"3","key":"394_CR11","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1086\/507488","volume":"79","author":"Z Zhao","year":"2006","unstructured":"Zhao Z, Tuakli-Wosornu Y, Lagace TA, Kinch L, Grishin NV, Horton JD, et al. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79(3):514\u201323.","journal-title":"Am J Hum Genet"},{"key":"394_CR12","doi-asserted-by":"crossref","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372.","DOI":"10.1093\/eurheartj\/ehx144"},{"key":"394_CR13","unstructured":"Regeneron Pharmaceuticals Inc., sanofi-aventis US LLC. Praluent prescribing information. 2015. Available from: http:\/\/products.sanofi.us\/praluent\/praluent.pdf. Accessed 30 Apr 2019."},{"key":"394_CR14","unstructured":"Sanofi. Praluent Prescribing Information. 2015. Available from: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125559Orig1s000lbledt.pdf. Accessed 19 July 2016."},{"key":"394_CR15","unstructured":"Amgen Inc. REPATHA Prescribing Information. 2015. Available from: https:\/\/www.pi.amgen.com\/~\/media\/amgen\/repositorysites\/pi-amgen-com\/repatha\/repatha_pi_hcp_english.pdf. Accessed 11 Mar 2019."},{"key":"394_CR16","unstructured":"Amgen Inc. Amgen receives NMPA approval for Repatha\u00ae (evolocumab) in china to reduce the risk of cardiovascular events. 2019. Available from: https:\/\/wwwext.amgen.com\/media\/news-releases\/2019\/01\/amgen-receives-nmpa-approval-for-repatha-evolocumab-in-china-to-reduce-the-risk-of-cardiovascular-events\/. Accessed 8 Mar 2019."},{"issue":"16","key":"394_CR17","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1489\u201399.","journal-title":"N Engl J Med"},{"issue":"22","key":"394_CR18","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"25","key":"394_CR19","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1016\/j.jacc.2012.03.007","volume":"59","author":"JM McKenney","year":"2012","unstructured":"McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 serine protease, SAR236553\/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59(25):2344\u201353.","journal-title":"J Am Coll Cardiol"},{"issue":"9836","key":"394_CR20","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(12)60771-5","volume":"380","author":"EA Stein","year":"2012","unstructured":"Stein EA, Gipe D, Bergeron J, Gaudet D, Weiss R, Dufour R, et al. Effect of a monoclonal antibody to PCSK9, REGN727\/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380(9836):29\u201336.","journal-title":"Lancet"},{"key":"394_CR21","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.atherosclerosis.2016.08.043","volume":"254","author":"EM Roth","year":"2016","unstructured":"Roth EM, Moriarty PM, Bergeron J, Langslet G, Manvelian G, Zhao J, et al. A phase III randomized trial evaluating alirocumab 300\u00a0mg every 4\u00a0weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. Atherosclerosis. 2016;254:254\u201362.","journal-title":"Atherosclerosis."},{"issue":"6","key":"394_CR22","doi-asserted-by":"publisher","first-page":"e003323","DOI":"10.1161\/JAHA.116.003323","volume":"5","author":"J Rey","year":"2016","unstructured":"Rey J, Poitiers F, Paehler T, Brunet A, DiCioccio AT, Cannon CP, et al. Relationship between low-density lipoprotein cholesterol, free proprotein convertase subtilisin\/kexin type 9, and alirocumab levels after different lipid-lowering strategies. J Am Heart Assoc. 2016;5(6):e003323.","journal-title":"J Am Heart Assoc."},{"issue":"16","key":"394_CR23","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMc1616623","volume":"376","author":"EM Roth","year":"2017","unstructured":"Roth EM, Goldberg AC, Catapano AL, Torri A, Yancopoulos GD, Stahl N, et al. Antidrug antibodies in patients treated with alirocumab. N Engl J Med. 2017;376(16):1589\u201390.","journal-title":"N Engl J Med"},{"issue":"6","key":"394_CR24","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499\u2013502.","journal-title":"Clin Chem"},{"issue":"12","key":"394_CR25","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJMoa1105803","volume":"366","author":"EA Stein","year":"2012","unstructured":"Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366(12):1108\u201318.","journal-title":"N Engl J Med"},{"issue":"20","key":"394_CR26","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1056\/NEJMoa1201832","volume":"367","author":"EM Roth","year":"2012","unstructured":"Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367(20):1891\u2013900.","journal-title":"N Engl J Med"},{"issue":"1","key":"394_CR27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40262-018-0669-y","volume":"58","author":"JM Martinez","year":"2019","unstructured":"Martinez JM, Brunet A, Hurbin F, DiCioccio AT, Rauch C, Fabre D. Population pharmacokinetic analysis of alirocumab in healthy volunteers or hypercholesterolemic subjects using a Michaelis\u2013Menten approximation of a target-mediated drug disposition model-support for a biologics license application submission: part I. Clin Pharmacokinet. 2019;58(1):101\u201313.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"394_CR28","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s40262-018-0670-5","volume":"58","author":"X Nicolas","year":"2019","unstructured":"Nicolas X, Djebli N, Rauch C, Brunet A, Hurbin F, Martinez JM, et al. Population pharmacokinetic\/pharmacodynamic analysis of alirocumab in healthy volunteers or hypercholesterolemic subjects using an indirect response model to predict low-density lipoprotein cholesterol lowering: support for a biologics license application submission: part II. Clin Pharmacokinet. 2019;58(1):115\u201330.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"394_CR29","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/1755-5922.12093","volume":"32","author":"C Lunven","year":"2014","unstructured":"Lunven C, Paehler T, Poitiers F, Brunet A, Rey J, Hanotin C, et al. A randomized study of the relative pharmacokinetics, pharmacodynamics, and safety of alirocumab, a fully human monoclonal antibody to PCSK9, after single subcutaneous administration at three different injection sites in healthy subjects. Cardiovasc Ther. 2014;32(6):297\u2013301.","journal-title":"Cardiovasc Ther"},{"issue":"1","key":"394_CR30","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.amjcard.2016.04.011","volume":"118","author":"T Teramoto","year":"2016","unstructured":"Teramoto T, Kobayashi M, Uno K, Takagi Y, Matsuoka O, Sugimoto M, et al. Efficacy and safety of alirocumab in Japanese subjects (Phase 1 and 2 studies). Am J Cardiol. 2016;118(1):56\u201363.","journal-title":"Am J Cardiol"},{"issue":"12","key":"394_CR31","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.amjcard.2016.08.072","volume":"118","author":"PH Jones","year":"2016","unstructured":"Jones PH, Bays HE, Chaudhari U, Pordy R, Lorenzato C, Miller K, et al. Safety of alirocumab (a PCSK9 monoclonal antibody) from 14 randomized trials. Am J Cardiol. 2016;118(12):1805\u201311.","journal-title":"Am J Cardiol"},{"key":"394_CR32","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.ijcard.2016.08.273","volume":"223","author":"M Farnier","year":"2016","unstructured":"Farnier M, Gaudet D, Valcheva V, Minini P, Miller K, Cariou B. Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: pooled analysis of eight ODYSSEY Phase 3 clinical program trials. Int J Cardiol. 2016;223:750\u20137.","journal-title":"Int J Cardiol"},{"issue":"14","key":"394_CR33","doi-asserted-by":"publisher","first-page":"11090","DOI":"10.1074\/jbc.M111.319764","volume":"287","author":"J Chaparro-Riggers","year":"2012","unstructured":"Chaparro-Riggers J, Liang H, DeVay RM, Bai L, Sutton JE, Chen W, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem. 2012;287(14):11090\u20137.","journal-title":"J Biol Chem"},{"issue":"10","key":"394_CR34","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s40262-016-0505-1","volume":"56","author":"N Djebli","year":"2017","unstructured":"Djebli N, Martinez JM, Lohan L, Khier S, Brunet A, Hurbin F, et al. Target-mediated drug disposition population pharmacokinetics model of alirocumab in healthy volunteers and patients: pooled analysis of randomized phase I\/II\/III studies. Clin Pharmacokinet. 2017;56(10):1155\u201371.","journal-title":"Clin Pharmacokinet"},{"key":"394_CR35","unstructured":"European Medicines Agency. European Public Assessment Report (EPAR) WC500194524. 2015. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Public_assessment_report\/human\/003882\/WC500194524.pdf. Accessed 30 Apr 2019."},{"key":"394_CR36","unstructured":"Calvier EAM, Martinez JM, Fabre D, Brunet A, Zhang YY. Alirocumab population pharmacokinetics in Chinese patients using priors. In: Annual meeting population approach group in Europe (PAGE), Stockholm. 2019. p. Abstr 8838."},{"issue":"5","key":"394_CR37","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.amjcard.2014.05.060","volume":"114","author":"D Gaudet","year":"2014","unstructured":"Gaudet D, Kereiakes DJ, McKenney JM, Roth EM, Hanotin C, Gipe D, et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin\/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150\u00a0mg every two weeks dosing from phase 2 trials). Am J Cardiol. 2014;114(5):711\u20135.","journal-title":"Am J Cardiol"},{"issue":"1","key":"394_CR38","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.amjcard.2016.09.010","volume":"119","author":"D Gaudet","year":"2017","unstructured":"Gaudet D, Watts GF, Robinson JG, Minini P, Sasiela WJ, Edelberg J, et al. Effect of alirocumab on lipoprotein(a) over \u2265 1.5 years (from the Phase 3 ODYSSEY program). Am J Cardiol. 2017;119(1):40\u20136","journal-title":"Am J Cardiol."},{"key":"394_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2019.10.015","author":"Y Han","year":"2019","unstructured":"Han Y, Chen J, Chopra V, Zhang S, Su G, Ma C, et al. ODYSSEY EAST: alirocumab efficacy and safety vs ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand. J Clin Lipidol. 2019. https:\/\/doi.org\/10.1016\/j.jacl.2019.10.015.","journal-title":"J Clin Lipidol."}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00394-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-020-00394-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-020-00394-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T02:07:35Z","timestamp":1613786855000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-020-00394-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,21]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["394"],"URL":"https:\/\/doi.org\/10.1007\/s40256-020-00394-1","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,21]]},"assertion":[{"value":"21 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Sanofi and Regeneron Pharmaceuticals, Inc. Open access publication of this manuscript was sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. The authors received no honoraria related to the development of this publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"HL, YW, ZY, SZ, and XX\u00a0are employees of the Peking University Third Hospital. MS, OV, YWW, MTB-D and JL\u00a0are employees of and shareholders in Sanofi. YZ\u00a0is an employee of and shareholder in Regeneron Pharmaceuticals, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the study participants were in accordance with the ethical standards of the independent ethics committee and with the 1964 Helsinki declaration and its later amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All participants provided written informed consent. No identifying information for individual subjects is included in this article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}